Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06238479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 5, 2024
Completion date
April 30, 2027
Enrollment
490 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, cervical cancer, esophageal cancer, head and neck squamous cell carcinoma, metastatic solid tumor, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, recurrent solid tumor, renal pelvis cancer, triple negative breast cancer, urinary bladder neoplasm